• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Director Hively Brad disposed of 353,450 shares and bought $50,000 worth of shares (300,000 units at $0.17), decreasing direct ownership by 7% to 666,753 units (SEC Form 4)

    12/2/24 4:04:53 PM ET
    $TOI
    Medical/Nursing Services
    Health Care
    Get the next $TOI alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Hively Brad

    (Last) (First) (Middle)
    C/O THE ONCOLOGY INSTITUTE INC.
    18000 STUDEBAKER RD, SUITE 800

    (Street)
    CERRITOS CA 90703

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Oncology Institute, Inc. [ TOI ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    11/12/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common stock 11/12/2024 J 353,450 D $0 366,753(1) D
    Common stock 11/26/2024 P 250,000 A $0.17 616,753(2) D
    Common stock 12/02/2024 P 50,000 A $0.15 666,753(2) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Reflects the forfeiture of restricted earn-out shares that were unvested due to failure to meet earnout targets of the Issuer's stock price of $12.50 and $15.00 per share for 20 days within any 30 consecutive trading days for the three-year period following November 12, 2021, the date of the closing of the Business Combination, subject to continued employment at such time.
    2. 44,000 being restricted stock units that vest in full on the date of the Company's 2025 annual meeting of stockholders, subject to continued service with the Company through such vesting date.
    Remarks:
    By: /s/ Mark Hueppelsheuser, Attorney-in-Fact for Brad Hively 12/02/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $TOI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TOI

    DatePrice TargetRatingAnalyst
    7/23/2025$8.00Outperform
    Noble Capital Markets
    7/16/2025$6.00Buy
    B. Riley Securities
    5/15/2025$7.00Buy
    BTIG Research
    2/26/2024$2.50Buy
    Jefferies
    9/14/2022$7.00Buy
    Guggenheim
    8/15/2022$10.00Buy
    Jefferies
    More analyst ratings

    $TOI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Noble Capital Markets initiated coverage on The Oncology Institute with a new price target

    Noble Capital Markets initiated coverage of The Oncology Institute with a rating of Outperform and set a new price target of $8.00

    7/23/25 9:21:53 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    B. Riley Securities initiated coverage on The Oncology Institute with a new price target

    B. Riley Securities initiated coverage of The Oncology Institute with a rating of Buy and set a new price target of $6.00

    7/16/25 7:58:29 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    BTIG Research initiated coverage on The Oncology Institute with a new price target

    BTIG Research initiated coverage of The Oncology Institute with a rating of Buy and set a new price target of $7.00

    5/15/25 8:12:51 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $TOI
    SEC Filings

    View All

    SEC Form 424B5 filed by The Oncology Institute Inc.

    424B5 - Oncology Institute, Inc. (0001799191) (Filer)

    8/13/25 5:20:16 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    SEC Form 10-Q filed by The Oncology Institute Inc.

    10-Q - Oncology Institute, Inc. (0001799191) (Filer)

    8/13/25 5:12:48 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    The Oncology Institute Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - Oncology Institute, Inc. (0001799191) (Filer)

    8/13/25 4:21:58 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $TOI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hively Brad sold $82,097 worth of shares (20,221 units at $4.06), decreasing direct ownership by 3% to 622,980 units (SEC Form 4)

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    8/21/25 3:13:31 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    SEC Form 4 filed by Director Barasch Richard A

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    8/14/25 3:49:53 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    Director Barasch Richard A disposed of 287,756 shares (SEC Form 4)

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    7/28/25 9:08:48 PM ET
    $TOI
    Medical/Nursing Services
    Health Care